1. What is the true risk of a pharmacokinetic drug–drug interaction?

   • Uwe Fuhr

   Editorial 08 August 2007 Pages: 897 - 899

2. Maintenance of indinavir by dose adjustment in HIV-1-infected patients with indinavir-related toxicity

   • J.-C. Wasmuth
   • I. Lambertz
   • J. K. Rockstroh

   Clinical Trial 10 August 2007 Pages: 901 - 908

   

3. An analysis of the clinical development of drugs in Norway for the years 2000 and 2004: the influence of the pharmaceutical industry

   • Finn O. Winther
   • Ola P. Hole
   • Sigurd Nitter-Hauge

   Debate Article 03 August 2007 Pages: 909 - 912

4. Interaction between a commercially available St. John’s wort product (Movina) and atorvastatin in patients with hypercholesterolemia

   • L. Andrén
   • Å Andreasson
   • R. Eggertsen

   Pharmacodynamics 15 August 2007 Pages: 913 - 916

5. Possible role of MDR1 two-locus genotypes for young-age onset ulcerative colitis but not Crohn’s disease

   • T. Fiedler
   • C. Büning
   • A. Johne

   Pharmacogenetics 31 July 2007 Pages: 917 - 925

   

6. Dose-escalation study of isoniazid in healthy volunteers with the rapid acetylator genotype of arylamine N-acetyltransferase 2

   • Ryuji Kubota
   • Masako Ohno
   • Junichi Azuma

   Pharmacogenetics 31 July 2007 Pages: 927 - 933

   

7. Tenofovir comedication does not impair the steady-state pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected adults

   • Nils von Hentig
   • Brenda Dauer
   • Sebastian Harder

   Pharmacokinetics and Disposition 31 July 2007 Pages: 935 - 940

   

8. Voriconazole and fluconazole increase the exposure to oral diazepam

   • Teijo I. Saari
   • Kari Laine
   • Klaus T. Olkkola

   Pharmacokinetics and Disposition 04 August 2007 Pages: 941 - 949

   

9. Gender-associated differences in pharmacokinetics and anti-arrhythmic effects of flecainide in Japanese patients with supraventricular tachyarrhythmia

   • Kosuke Doki
   • Masato Homma
   • Yukinao Kohda

   Pharmacokinetics and Disposition 31 July 2007 Pages: 951 - 957

   

10. Digoxin and mortality in atrial fibrillation: a prospective cohort study

    • Pär Hallberg
    • Johan Lindbäck
    • for the RIKS-HIA group

    Pharmacoepidemiology and Prescription 08 August 2007 Pages: 959 - 971

    

11. Adverse events of blood-pressure-lowering drugs: evidence of high incidence in a clinical setting

    • Carla B.C. Gonçalves
    • Leila B. Moreira
    • Flávio D. Fuchs

    Pharmacoepidemiology and Prescription 11 August 2007 Pages: 973 - 978

    

12. Patient-reporting of side effects may provide an important source of information in clinical practice

    • Juliet M. Foster
    • Thys van der Molen
    • Lolkje de Jong - van den Berg

    Letter to the Editors Open access 06 July 2007 Pages: 979 - 980

13. Reply to letter by Foster, van der Molen and de Jong-van den Berg

    • Pasi Lampela
    • Sirpa Hartikainen
    • Risto Huupponen

    Letter to the Editors 04 August 2007 Pages: 981 - 981